ECM
CGON icon

Everence Capital Management’s CG Oncology CGON Stock Holding History

Everence Capital Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Hold
3,744
– – 0.01% 687
2026
Q1 		$253K Buy
+3,744
New +$212K 0.02% 659

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Everence Capital Management's CGON Position: Q2 2026 in Review

Everence Capital Management held its CG Oncology (CGON) position steady in Q2 2026 at 3,744 shares worth $266K. The position accounts for 0.01% of the portfolio, ranked #687.

Everence Capital Management first reported a position in CGON in Q1 2026 and has held it in 2 quarters since. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Everence Capital Management held 3,744 shares of CG Oncology worth $266K as of Q2 2026.
  • Everence Capital Management left its CG Oncology share count unchanged in Q2 2026.
  • CG Oncology made up 0.01% of Everence Capital Management's portfolio in Q2 2026, its #687 holding.
  • Everence Capital Management first reported a position in CG Oncology in Q1 2026 and has held it in 2 quarters since.
  • 228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.